Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

NCT03376841 | Completed Phase 1 FDA Drug

• 1 other identifier: 3152-102-002
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 2

Brief Summary

The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability profiles of cenicriviroc (CVC) and its metabolites (M-I and M-II) in participants with severely impaired hepatic function compared with matched healthy participants following single-dose administration

Conditions

Hepatic Impairment

Keywords

Liver insufficiency; Hepatic Impairment; Cenicriviroc; Pharmacokinetics

Outcome Measures

Primary Outcomes (3)

• Area under the plasma concentration versus time curve (AUC) from time 0 to time t (AUC0-t)

  6 days (144 hours)

• AUC from time 0 to infinity (AUC0-∞)

  6 days (144 hours)

• Maximum plasma drug concentration (Cmax)

  6 days (144 hours)

Secondary Outcomes (5)

• Time of maximum plasma drug concentration (Tmax)

  6 days (144 hours)

• Terminal elimination rate constant

  6 days (144 hours)

• Terminal elimination half-life (T½)

  6 days (144 hours)

• Total body clearance of drug from plasma (CL/F for CVC only)

  6 days (144 hours)

• Volume of distribution during the terminal phase (Vz/F for CVC only)

  6 days (144 hours)

Study Arms (2)

Severe hepatic impairment

EXPERIMENTAL

Cenicriviroc tablet; single-dose oral administration

Drug: Cenicriviroc

Normal Hepatic function

EXPERIMENTAL

Cenicriviroc tablet; single-dose oral administration

Drug: Cenicriviroc

Interventions

Cenicriviroc DRUG

1 tablet; single-dose oral administration

Also known as: CVC

Normal Hepatic function; Severe hepatic impairment

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Sign the ICF and have the mental capability to understand it
• If female, have a negative result from a serum pregnancy test at screening and a negative result from a serum or urine pregnancy test on Day -1
• If male, agree to use an effective method of contraception (ie, condom plus diaphragm with spermicide or condom plus spermicide) and not have their partners become pregnant for at least 30 days after dosing study treatment, or have been sterilized for at least 1 year
• If female of childbearing potential, agree to use an effective method of contraception (ie, condom plus diaphragm with spermicide, condom plus spermicide, or nonhormonal intrauterine device) and not become pregnant for at least 30 days after dosing study treatment. Females who are at least 2 years postmenopausal (with supporting documentation from an obstetrician/gynecologist) or who have had tubal ligation or hysterectomy (with supporting documentation from the physician who performed the surgery) will not be considered to be of childbearing potential
• Be nonsmoking (never smoked or have not smoked in the previous 2 years) or a light smoker (fewer than 10 cigarettes per day within 1 week prior to study treatment administration)
• Have a body mass index (BMI) ≥ 18 kg/m2 and ≤ 42 kg/m2
• Have chronic liver disease and/or cirrhosis documented by the presence of at least 1 of the following:
• Liver biopsy with histologic findings consistent with cirrhosis
• Computerized tomographic or ultrasonographic evidence of liver disease with or without portal hypertension
• Physical examination and clinical and laboratory evidence of chronic liver disease
• Colloid shift on a liver-spleen scan

You may not qualify if:

• Known hypersensitivity to cenicriviroc and other chemokine receptor 2 and/or 5 (CCR2 and/or CCR5) antagonists such as maraviroc (CCR5 antagonist)
• History of substance abuse within the previous 2 years
• Dosing in any other clinical investigation using an experimental drug requiring repeated blood or plasma draws within 30 days of study treatment administration
• Participation in a blood or plasma donation program within 60 or 30 days, respectively, of study treatment administration
• Consumption of caffeine within 48 hours prior to dosing; consumption of grapefruit containing products, vegetables from the mustard green family (eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard), foods containing poppy seeds, and charbroiled meats within 14 days prior to dosing; or consumption of alcohol within 72 hours prior to dosing before study treatment administration
• Employee, or immediate relative of an employee, of the sponsor, any of its affiliates or partners, or the study center
• Previously taken cenicriviroc or previously participated in an investigational study of cenicriviroc
• Pregnant or breastfeeding (female participants)
• Have an acute exacerbation of liver disease as indicated by worsening clinical signs and/or laboratory tests within the 4 weeks before study treatment administration
• Have ascites that will require paracentesis within 1 week of dosing or during the study period
• Have gastrointestinal hemorrhage due to esophageal varices, peptic ulcers or Mallory Weiss Syndrome within 6 months before Day 1, unless banded and stable
• Have a Child-Pugh score of \< 10
• Any clinical condition other than hepatic impairment or previous surgery that might affect the absorption, distribution, biotransformation, or excretion of cenicriviroc and its metabolites

Sponsors & Collaborators

• Allergan: lead

Study Sites (2)

Clinical Pharmacology of Miami

Miami, Florida, 33014, United States

Location

Orlando Clinical Research Center

Orlando, Florida, 32809, United States

Location

Related Links

• Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.

MeSH Terms

Conditions

Hepatic Insufficiency

Interventions

cenicriviroc

Condition Hierarchy (Ancestors)

Liver Diseases; Digestive System Diseases

Study Officials

• Surya Ayalasomayajula

  Allergan

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 2, 2017
• First Posted: December 19, 2017
• Study Start: June 6, 2017
• Primary Completion: November 24, 2017
• Study Completion: December 17, 2017
• Last Updated: January 11, 2018

Record last verified: 2018-01

Locations

US (2)